156 related articles for article (PubMed ID: 38283732)
1. Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report.
Fang R; Xu S; Gong J; Liao Z
Onco Targets Ther; 2024; 17():27-31. PubMed ID: 38283732
[TBL] [Abstract][Full Text] [Related]
2. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
3. Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring
Yagami Y; Nakahara Y; Manabe H; Yamamoto H; Otani S; Sato T; Igawa S; Kubota M; Sasaki J; Naoki K
Onco Targets Ther; 2022; 15():1369-1374. PubMed ID: 36388158
[TBL] [Abstract][Full Text] [Related]
4. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
Zeng Q; Deng Y; Zhang L; Wang W
Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
6. Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report.
Su PL; Lin CY; Chen YL; Chen WL; Lin CC; Su WC
JTO Clin Res Rep; 2021 Aug; 2(8):100202. PubMed ID: 34590045
[TBL] [Abstract][Full Text] [Related]
7. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced
Xue Y; Ren Y; Yan B; Li Z; Huang C
Ann Transl Med; 2022 Sep; 10(18):1029. PubMed ID: 36267742
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
Li J; Wang Q; Ge J; Tian Y; Yao W
Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
[TBL] [Abstract][Full Text] [Related]
9. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S
BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631
[TBL] [Abstract][Full Text] [Related]
10. Severe Epistaxis Secondary to Dabrafenib and Trametinib Toxicity in Non-small Cell Lung Carcinoma With Small Bowel Metastasis.
Gullapalli K; Mosalem O; Varghese MT; Watat K; Hrinczenko B
Cureus; 2021 Jul; 13(7):e16431. PubMed ID: 34466299
[TBL] [Abstract][Full Text] [Related]
11. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.
Qu J; Shen Q; Li Y; Kalyani FS; Liu L; Zhou J; Zhou J
Front Oncol; 2022; 12():911303. PubMed ID: 35814395
[TBL] [Abstract][Full Text] [Related]
13. An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAF
Fang R; Gong J; Liao Z
Front Oncol; 2023; 13():1220745. PubMed ID: 37546400
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Dabrafenib Plus Trametinib Combination in Patients with
Auliac JB; Bayle S; Do P; Le Garff G; Roa M; Falchero L; Huchot E; Quéré G; Jeannin G; Métivier AC; Hobeika J; Guisier F; Chouaid C
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33276639
[TBL] [Abstract][Full Text] [Related]
16. Dabrafenib plus trametinib in patients with previously untreated BRAF
Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
[TBL] [Abstract][Full Text] [Related]
17. Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation.
Dotsu Y; Fukuda M; Honda N; Gyotoku H; Kohno Y; Suyama T; Umeyama Y; Taniguchi H; Takemoto S; Yamaguchi H; Miyazaki T; Sakamoto N; Obase Y; Ikeda H; Ashizawa K; Mukae H
Thorac Cancer; 2021 Jan; 12(2):272-276. PubMed ID: 33215864
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract][Full Text] [Related]
19. Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation.
Seo T; Noguchi E; Yoshida M; Mori T; Tanioka M; Sudo K; Shimomura A; Yonemori K; Fujiwara Y; Tamura K
Case Rep Oncol Med; 2020; 2020():2518383. PubMed ID: 32206360
[TBL] [Abstract][Full Text] [Related]
20. Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer.
Moschetta M; Mak G; Hauser J; Davies C; Uccello M; Arkenau HT
Exp Hematol Oncol; 2017; 6():1. PubMed ID: 28078189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
